| Megan Fuka, OTD, OTR/L | |
|
8100 Northland Dr, Bloomington, MN 55431-4800 | |
| (952) 831-8742 | |
| Not Available |
| Full Name | Megan Fuka |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist - Hand |
| Location | 8100 Northland Dr, Bloomington, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225774086 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XH1200X | Occupational Therapist - Hand | (* (Not Available)) | Primary |
| Provider Name | Park Nicollet Clinic |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1780621904 PECOS PAC ID: 7911819438 Enrollment ID: O20031104000046 |
News Archive
A groundbreaking study could help to revolutionise the way in which mental health service users and their carers plan their care.
Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, announced today it has completed a $35 million Series A financing co-led by Flagship Ventures and Third Rock Ventures. Proceeds from the financing will be used to build the research and development and business development teams for Eleven Biotherapeutics, in addition to advancing the company's portfolio of engineered proteins through clinical proof of concept.
Echoing recent FDA warnings, a research group from Northern Ireland cautions against over-aggressive use of a group of drugs called "erythropoiesis-stimulating agents" (ESAs) to treat anemia in some cancer patients, according to a commentary in the April issue of The Oncologist, published by AlphaMed Press.
Novel menin-KMT2A inhibitor appears to be safe and well-tolerated. FLT3 inhibitor plus low-dose chemotherapy shows promising efficacy and safety. Results represent encouraging news on hard-to-treat AML subtypes.
A new study in American veterans posted to the medRxiv* preprint server suggests severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are less effective in preventing infection after six months. The decline was most significant with the Johnson & Johnson vaccine, with vaccine effectiveness plummeting from 88% to 3%.
› Verified 3 days ago
| Provider Name | Tria Orthopaedic Center Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1518273085 PECOS PAC ID: 3173570561 Enrollment ID: O20110310000999 |
News Archive
A groundbreaking study could help to revolutionise the way in which mental health service users and their carers plan their care.
Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, announced today it has completed a $35 million Series A financing co-led by Flagship Ventures and Third Rock Ventures. Proceeds from the financing will be used to build the research and development and business development teams for Eleven Biotherapeutics, in addition to advancing the company's portfolio of engineered proteins through clinical proof of concept.
Echoing recent FDA warnings, a research group from Northern Ireland cautions against over-aggressive use of a group of drugs called "erythropoiesis-stimulating agents" (ESAs) to treat anemia in some cancer patients, according to a commentary in the April issue of The Oncologist, published by AlphaMed Press.
Novel menin-KMT2A inhibitor appears to be safe and well-tolerated. FLT3 inhibitor plus low-dose chemotherapy shows promising efficacy and safety. Results represent encouraging news on hard-to-treat AML subtypes.
A new study in American veterans posted to the medRxiv* preprint server suggests severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are less effective in preventing infection after six months. The decline was most significant with the Johnson & Johnson vaccine, with vaccine effectiveness plummeting from 88% to 3%.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Megan Fuka, OTD, OTR/L 8100 Northland Dr, Bloomington, MN 55431-4800 Ph: (952) 831-8742 | Megan Fuka, OTD, OTR/L 8100 Northland Dr, Bloomington, MN 55431-4800 Ph: (952) 831-8742 |
News Archive
A groundbreaking study could help to revolutionise the way in which mental health service users and their carers plan their care.
Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, announced today it has completed a $35 million Series A financing co-led by Flagship Ventures and Third Rock Ventures. Proceeds from the financing will be used to build the research and development and business development teams for Eleven Biotherapeutics, in addition to advancing the company's portfolio of engineered proteins through clinical proof of concept.
Echoing recent FDA warnings, a research group from Northern Ireland cautions against over-aggressive use of a group of drugs called "erythropoiesis-stimulating agents" (ESAs) to treat anemia in some cancer patients, according to a commentary in the April issue of The Oncologist, published by AlphaMed Press.
Novel menin-KMT2A inhibitor appears to be safe and well-tolerated. FLT3 inhibitor plus low-dose chemotherapy shows promising efficacy and safety. Results represent encouraging news on hard-to-treat AML subtypes.
A new study in American veterans posted to the medRxiv* preprint server suggests severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are less effective in preventing infection after six months. The decline was most significant with the Johnson & Johnson vaccine, with vaccine effectiveness plummeting from 88% to 3%.
› Verified 3 days ago
Christina Jean Jensen, OT Occupational Therapist Medicare: Medicare Enrolled Practice Location: 4801 W 81st St Ste 112, Bloomington, MN 55437 Phone: 952-345-3000 Fax: 952-345-6789 | |
Ms. Sandra Marie Meyer, OTR L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3800 American Blvd W, The Hartford, Bloomington, MN 55431 Phone: 952-656-6321 | |
Kim M Waterbury, MS, OTRL, CHT Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 8100 Northland Dr, Bloomington, MN 55431 Phone: 952-831-8742 | |
Bailey Paige O'connell, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1801 American Blvd E, Bloomington, MN 55425 Phone: 952-767-2267 | |
Ms. Nancy J Callinan, OT Occupational Therapist Medicare: Medicare Enrolled Practice Location: 8100 Northland Dr, Bloomington, MN 55431 Phone: 952-831-8742 | |
Jennifer Shana Voorhees, OTR L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 900 West 94th Street, Bloomington, MN 55420 Phone: 952-885-0418 Fax: 952-885-0173 | |
Anna Kate Restemayer, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4801 W 81st St Ste 112, Bloomington, MN 55437 Phone: 952-345-3000 Fax: 952-345-6789 |